The oncogenic hallmark of PCNSL is the activation of the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), driven by constitutive activation of signaling through the B cell receptor (BCR) and Toll-like receptor (TLR) [19]. This evidence concerns the gene NFKB1 and primary central nervous system lymphoma.